Randomized Trial of Ceftazidime-Avibactam Vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses Per US FDA-Specified End Points

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2019 May 2

PMID 31041348

Citations 22

Authors

Antoni Torres

Doug Rank

David Melnick

Ludmyla Rekeda

Xiang Chen

Todd Riccobene

Ian A Critchley

Hassan D Lakkis

Dianna Taylor

Angela K Talley

Affiliations

Soon will be listed here.

Abstract

Background: Hospital-acquired and ventilator-associated pneumonia (HAP/VAP; nosocomial pneumonia) due to Gram-negative pathogens are associated with significant morbidity and mortality; treatment options for multidrug-resistant infections are limited. The pivotal phase III REPROVE trial evaluated the efficacy of ceftazidime-avibactam (CAZ-AVI) vs meropenem in the treatment of patients with HAP/VAP. Study results for prespecified analyses per US Food and Drug Administration-recommended trial end points are reported here.

Methods: Hospitalized adults with HAP/VAP proven or suspected to be caused by a Gram-negative pathogen were randomized 1:1 to receive CAZ-AVI or meropenem for 7 to 14 days. The primary outcome was 28-day all-cause mortality in the intent-to-treat (ITT) population. Secondary outcomes included clinical cure at test of cure (TOC) in the ITT and microbiological ITT (micro-ITT) populations, and safety and tolerability throughout the study.

Results: hundred seventy randomized patients received treatment and were included in the ITT population (CAZ-AVI, n = 436; meropenem, n = 434). CAZ-AVI was noninferior to meropenem for the primary end point (28-day all-cause mortality; ITT) based on the prespecified 10% noninferiority margin (CAZ-AVI, 9.6%; meropenem, 8.3%; difference, 1.5%; 95% confidence interval [CI], -2.4% to 5.3%) and for the clinical cure end point in the ITT population based on a prespecified -10% noninferiority margin (CAZ-AVI, 67.2%; meropenem, 69.1%; difference, -1.9%; 95% CI, -8.1% to 4.3%). Clinical cure rates at TOC for patients infected with CAZ-nonsusceptible pathogens were similar (CAZ-AVI, 75.5%; meropenem, 71.2%; micro-ITT). Safety data were consistent with established safety profiles for both agents.

Conclusions: CAZ-AVI provides an important new treatment option for HAP/VAP due to Gram-negative pathogens, including CAZ-nonsusceptible strains.

Citing Articles

Estimating the value of new antibiotic treatment strategies in Zhejiang province, China: cost-effectiveness analysis based on a validated dynamic model.

Yang W, Zhen X, Sun X, Khatiwada S, Yang D, Chen Y BMJ Open. 2024; 14(8):e086039.

PMID: 39209783 PMC: 11367305. DOI: 10.1136/bmjopen-2024-086039.

Novel Siderophore Cephalosporin and Combinations of Cephalosporins with β-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia.

Viscardi S, Topola E, Sobieraj J, Duda-Madej A Antibiotics (Basel). 2024; 13(5).

PMID: 38786173 PMC: 11117516. DOI: 10.3390/antibiotics13050445.

Effectiveness of Ceftazidime-Avibactam in Gram-Negative Nosocomial Pneumonia: A Real-World Study in India.

Gupta N, Saseedharan S, Paliwal Y Cureus. 2024; 16(2):e54443.

PMID: 38510907 PMC: 10951683. DOI: 10.7759/cureus.54443.

Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pneumonia for Patients Who Are Morbidly Obese.

Kunz Coyne A, Orzol C, Veve M, Rybak M Open Forum Infect Dis. 2023; 10(9):ofad454.

PMID: 37720698 PMC: 10500045. DOI: 10.1093/ofid/ofad454.

The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference.

Dequin P, Aubron C, Faure H, Garot D, Guillot M, Hamzaoui O Ann Intensive Care. 2023; 13(1):59.

PMID: 37400647 PMC: 10317910. DOI: 10.1186/s13613-023-01155-4.

References

Capitano B, Nicolau D, Potoski B, Byers K, Horowitz M, Venkataramanan R . Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy. 2004; 24(6):803-7. DOI: 10.1592/phco.24.8.803.36070. View

Lorente L, Lorenzo L, Martin M, Jimenez A, Mora M . Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006; 40(2):219-23. DOI: 10.1345/aph.1G467. View

Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A . Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med. 2006; 100(9):1554-65. DOI: 10.1016/j.rmed.2006.01.004. View

Siempos I, Vardakas K, Manta K, Falagas M . Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J. 2007; 29(3):548-60. DOI: 10.1183/09031936.00080206. View

Wang D . Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2008; 33(3):290-1. DOI: 10.1016/j.ijantimicag.2008.09.012. View

Jones R . Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010; 51 Suppl 1:S81-7. DOI: 10.1086/653053. View

Melsen W, Rovers M, Koeman M, Bonten M . Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med. 2011; 39(12):2736-42. DOI: 10.1097/CCM.0b013e3182281f33. View

Timsit J, Zahar J, Chevret S . Attributable mortality of ventilator-associated pneumonia. Curr Opin Crit Care. 2011; 17(5):464-71. DOI: 10.1097/MCC.0b013e32834a5ae9. View

van Duin D, Kaye K, Neuner E, Bonomo R . Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013; 75(2):115-20. PMC: 3947910. DOI: 10.1016/j.diagmicrobio.2012.11.009. View

10.

Zhanel G, Lawson C, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens P . Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013; 73(2):159-77. DOI: 10.1007/s40265-013-0013-7. View

11.

. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013; 62(9):165-70. PMC: 4604788. View

12.

Dimopoulos G, Poulakou G, Pneumatikos I, Armaganidis A, Kollef M, Matthaiou D . Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest. 2013; 144(6):1759-1767. DOI: 10.1378/chest.13-0076. View

13.

Sader H, Farrell D, Flamm R, Jones R . Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014; 43(4):328-34. DOI: 10.1016/j.ijantimicag.2014.01.007. View

14.

Magill S, Edwards J, Bamberg W, Beldavs Z, Dumyati G, Kainer M . Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370(13):1198-208. PMC: 4648343. DOI: 10.1056/NEJMoa1306801. View

15.

Pugh R, Grant C, Cooke R, Dempsey G . Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015; (8):CD007577. PMC: 7025798. DOI: 10.1002/14651858.CD007577.pub3. View

16.

Mazuski J, Gasink L, Armstrong J, Broadhurst H, Stone G, Rank D . Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis. 2016; 62(11):1380-1389. PMC: 4872289. DOI: 10.1093/cid/ciw133. View

17.

Micek S, Chew B, Hampton N, Kollef M . A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes. Chest. 2016; 150(5):1008-1014. PMC: 7094544. DOI: 10.1016/j.chest.2016.04.009. View

18.

Carmeli Y, Armstrong J, Laud P, Newell P, Stone G, Wardman A . Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised,.... Lancet Infect Dis. 2016; 16(6):661-673. DOI: 10.1016/S1473-3099(16)30004-4. View

19.

Wagenlehner F, Sobel J, Newell P, Armstrong J, Huang X, Stone G . Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016; 63(6):754-762. PMC: 4996135. DOI: 10.1093/cid/ciw378. View

20.

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View